Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria

NCT07224776 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.

NCT NCT07224776
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07224776 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
Lead sponsor
Brigham and Women's Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
July 10, 2026
Completion date
December 1, 2028
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

proteinuria, proteinuria in nephrotic range, proteinuric kidney disease, proteinuric renal disease